Trial · NCT07391761
A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan
NCT07391761, Active not recruiting, Pfizer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan. Trials, record NCT07391761. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07391761
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan
- NCT number
- NCT07391761
- Status
- Active not recruiting
- Enrollment
- 1 participants, estimated
- Lead sponsor
- Pfizer
- Conditions
- Refractory Multiple Myeloma (RRMM)
- Interventions
- Non intervention
- First posted
- 2026-02-06
- Last updated
- 2026-07-01
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | rwTTR (real-world time to response) | At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.) | Time from index date to the first documented real-world response. |
| Primary | rwORR (real-world overall response rate) | At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.) | Proportion of patients achieving real-world overall response at predefined assessment time points. |
| Primary | rwDOR (real-world duration of response） | From first response until 18 months | Time from the first documented real-world response to real-world disease progression, death, or end of study. |
| Primary | rwPFS (real-world progression-free survival) | From initiation of elranatamab treatment (index date) until 18 months | Time from index date to the first documented real-world disease progression or death. |
| Primary | rwOS (real world overall survival) | From initiation of elranatamab treatment (index date) until 18 months | Time from index date to death from any cause. |
| Primary | rwTTNT (real world time to next treatment) | From initiation of elranatamab treatment (index date) until 18 months | Time from index date to initiation of the next line of anti-myeloma therapy or end of study. |
| Secondary | Demographic: Age | At baseline | Age (measured in years) |
| Secondary | Demographic: Sex | From MM diagnosis until index date, and from index date until 18 months | sex/gender (male/female) |
| Secondary | Anthropometric Measures | At baseline | Height (in cm), weight (in kg), BMI (kg/m²), |
| Secondary | ECOG Performance Status | At baseline | Number and proportion of patients in each ECOG PS category (0-5) |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07391761
GET https://conductscience.org/api/trials/v1/NCT07391761/registered